Author: ash

News
July 11, 2025 Comment off

Swiss approval opens door for first malaria treatment in tiny infants

GENEVA, July 11 — Swiss regulators have approved the first-ever antimalarial drug specifically designed for newborns weighing less than 11 pounds, marking a breakthrough in efforts to treat the disease in the most vulnerable infants. Pharmaceutical giant Novartis developed the new formulation of artemether-lumefantrine, designed as a cherry-flavored, rapidly dissolving tablet that can be given […]

Read more
News
July 9, 2025 Comment off

First-ever herpes-based therapy to treat severe skin cancer could soon be approved

Los Angeles, 9 July — A genetically modified herpes simplex virus, RP1, in combination with nivolumab, has shown the ability to shrink and even eliminate advanced melanoma tumors—including those not directly injected—in early clinical trials. This pioneering approach in oncolytic virotherapy offers hope for patients with treatment-resistant melanoma. In a phase 1/2 trial involving 140 patients […]

Read more
News
July 5, 2025 Comment off

New Neurons Still Form in the Adult Brain — Even in Late Life

STOCKHOLM, July 5, 2025 – New research from Sweden’s Karolinska Institutet has confirmed that the human brain continues to generate new neurons in the hippocampus well into later life. The findings, published in the journal Science, challenge long-standing beliefs that adult neurogenesis is negligible or absent in older adults. The team examined postmortem brain samples […]

Read more
News
July 3, 2025 Comment off

International medical graduates blocked from starting US residencies

WASHINGTON, July 3, 2025 – Hundreds of international medical graduates (IMGs) who matched to U.S. residency programs this year are unable to begin their training due to delays and denials in securing J-1 visas. The issue is leaving hospitals across the country understaffed, especially in underserved and rural areas that rely heavily on foreign-trained doctors. […]

Read more